此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Improving Hospital-To-Methadone Clinic Connection Using Implementation Support for Patients With Opioid Use Disorder (HOTPIN-IF)

2026年5月13日 更新者:University of Colorado, Denver

Facilitating In-Hospital Opioid Treatment Program Intakes to Support Hospital to OTP Linkage Among Hospitalized Patients With Opioid Use Disorder: An Implementation Trial in Four Hospitals

The goal of this clinical trial is to learn if a hospital-based approach can help people with opioid use disorder (OUD) connect to a methadone clinic after leaving the hospital. This study focuses on adults with OUD who are in the hospital and want to start methadone treatment. Methadone is a safe and effective treatment for OUD. It can reduce cravings, prevent withdrawal, and lower the risk of overdose and death. Even though methadone works well, many people do not receive it. For people who start treatment in the hospital, the time after discharge is a high-risk period. Many patients do not connect to a methadone clinic after they leave. This can lead to return to opioid use, overdose, repeat hospital visits, and poor health. This study tests a new approach where hospital teams help complete the methadone clinic intake during the hospital stay. This approach uses trained hospital staff and structured workflows to complete key parts of the intake process before discharge. The goal is to reduce delays and make it easier for patients to connect to care right after leaving the hospital. The main questions it aims to answer are: 1) Does completing a methadone clinic intake during the hospital stay increase the number of people who connect to a methadone clinic after discharge? 2) Does providing support to hospital teams increase how often these in-hospital intakes are completed? Researchers will compare usual hospital care (referral at discharge) to a hospital-based approach that helps complete methadone clinic intake during the hospital stay to see if this improves connection to care.

研究概览

地位

尚未招聘

详细说明

The purpose of this study is to test whether a hospital-based approach can improve connection to methadone treatment after discharge. The approach includes completing OTP intake during hospitalization and supporting hospital teams through an implementation strategy called implementation facilitation (IF). This study also aims to understand how well the approach can be adopted and sustained across different hospitals. This is a multi-site clinical trial conducted at four hospitals. The study uses a hybrid type 2 implementation-effectiveness design, meaning it evaluates both patient outcomes and how the intervention is implemented. The study uses an incomplete stepped wedge cluster randomized design. In this design:

  • All hospitals begin in a usual care phase
  • Hospitals are randomly assigned a time to switch to the intervention
  • Over time, each hospital transitions from usual care to the intervention phase
  • This allows each hospital to serve as its own comparison

During the usual care phase, patients receive standard care, which includes referral to an OTP at discharge. During the intervention phase, hospital teams receive implementation support to help complete OTP intake during the hospital stay. The intervention is an implementation strategy designed to support hospital teams in completing OTP intake during hospitalization.

The study uses the RE-AIM framework to evaluate outcomes:

  • Reach: The number and characteristics of patients who complete OTP intake and connect to care.
  • Effectiveness: The primary outcome is connection to an OTP after hospital discharge (for example, within 7 days). Secondary outcomes may include engagement in treatment at 30 and 90 days, healthcare use, and mortality.
  • Adoption: The proportion of hospital clinicians and teams who use the new workflows and complete OTP intake.
  • Implementation: How well the intervention is delivered, including fidelity to core components, adaptations, and resources used.
  • Maintenance: Whether the intervention is sustained over time after initial implementation.

The study will also assess implementation costs and identify barriers and facilitators to adoption.

Participants are adults with OUD who are hospitalized and interested in starting methadone treatment. Participants must be willing to connect to a methadone clinic after discharge.

Data will be collected from multiple sources, including:

  • Electronic health records (EHRs) from participating hospitals
  • Data from opioid treatment programs (when available)
  • Study questionnaires completed during enrollment
  • Administrative data on healthcare use
  • National Death Index data for mortality outcomes
  • Data will be combined across sites using a structured data approach to ensure consistency.

The analysis will evaluate:

  • Differences in OTP connection rates
  • Changes in treatment engagement over time
  • Variation across hospitals
  • Implementation outcomes and costs
  • Qualitative data from interviews and observations may also be used to understand how the intervention works in real-world settings.

This study addresses a major gap in care for people with OUD. Improving connection to methadone treatment after hospitalization has the potential to reduce overdose deaths, improve health outcomes, and reduce healthcare use. By testing both effectiveness and implementation, this study will provide practical information for scaling this approach across hospitals.

If successful, this model could be widely adopted to improve access to life-saving treatment for people with OUD.

研究类型

介入性

注册 (估计的)

1440

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age ≥18 years
  • Hospitalized with DSM-5 opioid use disorder, confirmed by clinical assessment
  • Eligible for methadone treatment as determined by the clinical team
  • Not currently enrolled in an Opioid Treatment Program (OTP)
  • Anticipated discharge to the community
  • Willing to initiate methadone and follow up at a partnering OTP

Exclusion Criteria:

  • Current enrollment in an Opioid Treatment Program (OTP)
  • Planned discharge to a correctional or institutional setting that precludes OTP follow-up
  • Medical or psychiatric instability that precludes safe methadone initiation or completion of study procedures
  • Inability to provide required information for OTP intake due to impaired cognition or altered mental status

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:不适用
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Usual Care
Standard hospital-to-OTP referral processes without implementation facilitation

Participants receive care at sites after rollout of Implementation Facilitation (IF) to support HOTPIN workflows.

Focus on completing in-hospital OTP intake, including:

Medical assessment Screening labs Methadone initiation Transportation coordination

Supported by:

External facilitators Learning collaboratives Workflow integration into the EHR

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
7-Day Hospital-to-OTP Linkage
大体时间:Measured within 7 days following hospital discharge

The primary outcome is whether a participant successfully connects to an Opioid Treatment Program (OTP) within 7 days after hospital discharge. Connection" (linkage) is defined as:

Completion of OTP intake and/or attendance at the OTP, and Receipt or continuation of methadone treatment at the OTP

Measured within 7 days following hospital discharge

次要结果测量

结果测量
措施说明
大体时间
30-Day OTP Engagement
大体时间:30 days after hospital discharge

Description:

Proportion of participants who remain engaged in methadone treatment at an Opioid Treatment Program (OTP) within 30 days after hospital discharge.

Defined by ongoing dosing or documented attendance at the OTP Reflects short-term treatment retention

30 days after hospital discharge
90-Day OTP Engagement (Retention)
大体时间:Within 90 days after hospital discharge

Description:

Proportion of participants who remain engaged in methadone treatment at an OTP within 90 days after hospital discharge.

Defined by continued dosing records or clinic attendance Reflects longer-term treatment retention

Within 90 days after hospital discharge

其他结果措施

结果测量
措施说明
大体时间
Healthcare Utilization After Discharge
大体时间:90 days following hospital discharge

Description:

Rates of emergency department visits and hospital readmissions following the index hospitalization.

Assessed using hospital administrative and EHR data

90 days following hospital discharge
All-cause mortality following hospital discharge.
大体时间:90 days after hospital disharge
Assessed using linkage to the National Death Index (NDI)
90 days after hospital disharge

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Susan L Calcaterra, MD, MPH, MS、University of Colorado, Denver

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2030年10月31日

研究完成 (估计的)

2030年11月30日

研究注册日期

首次提交

2026年4月24日

首先提交符合 QC 标准的

2026年4月30日

首次发布 (实际的)

2026年5月6日

研究记录更新

最后更新发布 (实际的)

2026年5月18日

上次提交的符合 QC 标准的更新

2026年5月13日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

We will share de-identified individual participant data (IPD) using a controlled access process (not open download)

We will require:

Data Use Agreement (DUA) IRB approval or exemption data security plan

We will exclude:

Direct identifiers Anything restricted under 42 CFR Part 2 without proper authorization

IPD 共享时间框架

Time Frame:

Data will be available beginning 12 months after publication of the primary results and ending 5 years after publication.

IPD 共享访问标准

Data will be shared with investigators who provide a methodologically sound proposal. Access will require execution of a Data Use Agreement (DUA), Institutional Review Board (IRB) approval or exemption, and adherence to data security requirements.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅